Corcept Therapeutics CORT Q2 2026: Cancer Drug Lifyorli Fuels 671% EPS Beat
As seen on the 24/7 Wall St. homepage on July 29, 2026.
Corcept crushed earnings by 671% as its newly approved cancer drug Lifyorli generated $47.6 million in its first full quarter, with over 1,300 patients already on treatment and monthly demand accelerating. The company raised full-year guidance to $1.1 billion to $1.2 billion on the strength of both the oncology launch and record new prescriptions in its core Cushing's syndrome franchise.
Continue ReadingShow less
Corcept Therapeutics reported Q2 2026 earnings per share of $0.36 against a consensus estimate of roughly $0.04, a beat of 671%. Revenue came in at $256.1 million for the quarter, topping estimates of $220 million by about 16%, and marking the strongest quarter in the company's recent history — well above the $194.4 million it posted in Q2 2025.
The standout driver was Lifyorli, Corcept's newly approved cancer drug, which generated $47.6 million in its first full quarter on the market. More than 1,300 patients are already on treatment, and monthly demand continues to accelerate. At the same time, the company's core Cushing's syndrome franchise set a record for new prescriptions, meaning growth is coming from both ends of the portfolio.
Sponsored
_________________________________
What's Your Number...?
Here's a question most people 5y from retirement can't answer: at your current savings rate, how much do you need, and how long will it actually last? A good advisor can put a date on that in a single meeting. SmartAsset's free quiz matches you with up to three fiduciary advisors serving your area, so you can get YOUR retirement number now (sponsor)
__________________________________________
On the strength of the oncology launch and the Cushing's momentum, Corcept raised its full-year revenue guidance to a range of $1.1 billion to $1.2 billion. That outlook reflects a business that has visibly shifted from a single-franchise story to one with a second commercial product gaining traction fast.
Mentioned: CORT